Investigating how certain proteins respond to toxic compounds in the body.
A novel family of conserved glyoxal toxicity response proteins.
This study is looking at how certain proteins in bacteria help them deal with harmful substances produced during normal metabolism, which could lead to new ways to help our bodies better handle these toxins and improve our health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11010748 on NIH RePORTER |
What this research studies
This research focuses on understanding how a specific class of proteins, known as Antibiotic Monooxygenase (ABM) domains, detect and respond to toxic dicarbonyl molecules like glyoxal, which are produced during normal metabolism. By studying these proteins in the bacterial pathogen Pseudomonas aeruginosa, the research aims to uncover the mechanisms that help cells manage the harmful effects of glyoxal. This knowledge could lead to new strategies for enhancing health and longevity by improving the body's ability to detoxify these harmful compounds.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for or suffering from conditions related to glyoxal toxicity, including diabetes, cardiovascular diseases, and age-related disorders.
Not a fit: Patients who do not have any of the conditions associated with glyoxal toxicity or who are not at risk for these diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that help prevent or mitigate diseases associated with glyoxal toxicity, such as diabetes, heart disease, and aging.
How similar studies have performed: While the specific approach of studying ABM domains in relation to glyoxal is novel, research on dicarbonyl stress and its implications for health has shown promising results in related fields.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Ulijasz, Andrew T — University of Alabama at Birmingham
- Study coordinator: Ulijasz, Andrew T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.